$288.18
1.64% day before yesterday
NYSE, May 30, 10:13 pm CET
ISIN
US0311621009
Symbol
AMGN
Sector
Industry

Amgen Stock price

$288.18
-2.74 0.94% 1M
+10.08 3.62% 6M
+27.54 10.57% YTD
-12.82 4.26% 1Y
+32.92 12.90% 3Y
+61.27 27.00% 5Y
+131.15 83.52% 10Y
NYSE, Closing price Fri, May 30 2025
+4.64 1.64%
ISIN
US0311621009
Symbol
AMGN
Sector
Industry

Key metrics

Market capitalization $154.96b
Enterprise Value $203.53b
P/E (TTM) P/E ratio 26.29
EV/FCF (TTM) EV/FCF 18.65
EV/Sales (TTM) EV/Sales 5.96
P/S ratio (TTM) P/S ratio 4.54
P/B ratio (TTM) P/B ratio 24.96
Dividend yield 3.12%
Last dividend (FY24) $9.00
Revenue growth (TTM) Revenue growth 15.56%
Revenue (TTM) Revenue $34.13b
EBIT (operating result TTM) EBIT $8.61b
Free Cash Flow (TTM) Free Cash Flow $10.92b
Cash position $8.81b
EPS (TTM) EPS $10.96
P/E forward 21.46
P/S forward 4.39
EV/Sales forward 5.77
Short interest 2.68%
Show more

Create a Free Account to create an Amgen alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Amgen Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a Amgen forecast:

14x Buy
42%
16x Hold
48%
3x Sell
9%

Analyst Opinions

33 Analysts have issued a Amgen forecast:

Buy
42%
Hold
48%
Sell
9%

Financial data from Amgen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
34,126 34,126
16% 16%
100%
- Direct Costs 12,263 12,263
23% 23%
36%
21,863 21,863
12% 12%
64%
- Selling and Administrative Expenses 6,975 6,975
4% 4%
20%
- Research and Development Expense 6,107 6,107
21% 21%
18%
14,188 14,188
22% 22%
42%
- Depreciation and Amortization 5,580 5,580
22% 22%
16%
EBIT (Operating Income) EBIT 8,608 8,608
22% 22%
25%
Net Profit 5,933 5,933
58% 58%
17%

In millions USD.

Don't miss a Thing! We will send you all news about Amgen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amgen Stock News

Neutral
PRNewsWire
2 days ago
THOUSAND OAKS, Calif. , May 30, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:20 a.m.
Positive
Reuters
2 days ago
Amgen's Nplate, which treats low blood platelet counts caused by an autoimmune condition, was highly effective at preventing a similar common and serious complication of powerful chemotherapy cancer drugs, researchers reported ahead of the American Society of Clinical Oncology meeting in Chicago.
Positive
The Motley Fool
3 days ago
Amgen (AMGN -0.36%) is doing something unusual in 2025. The biotech giant's shares are up 7.2% for the year as I write this while most large-cap healthcare stocks struggle; yet it trades at just 13 times forward earnings estimates compared to 21 for the S&P 500.
More Amgen News

Company Profile

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Head office United States
CEO Robert Bradway
Employees 28,000
Founded 1980
Website www.amgen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today